Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid Limited continues growth in Japan, set for sales increase

Cellmid Limited continues growth in Japan, set for sales increase

Cellmid (ASX:CDY) delivered an increase of 108% in revenue across the Consumer Health Division at over $1.2 million for H1 FY2016, compared with the same period last year (FY2015: $582K).

There is the potential for a further expansion, as the company has completed brand building activities and commencement of the advertising campaign to drive customer traffic to pharmacies in Australia.

Cellmid also has a planned launch of the évolis® Professional range in Australia, which has 13 products for salons, in June 2016.


Cellmid’s Japanese sales continued to strengthen at $949K, a 133% increase from the same period in the previous year (2015: $407K).

évolis® concept store in Tokyo planned to open in late CY2016. Other Japanese retail opportunities are expected to start from the last quarter on FY2016.


Cellmid has refinanced the R&D loan agreement originally entered into with Platinum Road on 15 May 2015.

The original $1,000,000 loan facility and interest was repaid by a new $700,000 loan and cash.

Together with the company’s existing cash reserves the funds will be used to continue the development of the CAB102 midkine (MK) antibody program and invest into the international distribution opportunities for the évolis® product range.


With Cellmid’s expansion in both the pharmacy and salon markets in Australia, the continued growth in Japan, and with the planned drive into major international markets - the company is poised for a significant increase in sales in FY2016 and beyond.

This also has the potential to alleviate the need for a further capital raise.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Register here to be notified of future CDY Company articles
View full CDY profile

Cellmid Ltd Timeline

October 28 2016
October 26 2016
October 18 2016

Related Articles

February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
World map made out of drugs
November 08 2016
The pharma services and drug development group has hit key milestones in the last year.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.